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population and economy against potentially troublesome and resource intensive 
outbreaks of infectious diseases.
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Objectives: A new scenario of therapy for HCV infection is being established 
with the approval. The aim of this study is to evaluate the long-term health out-
comes and the willingness to pay of new anti-HCV treatment from the Italian soci-
etal perspective. MethOds: A multistate model was developed to estimate the 
HCV-infection process in a theoretical cohort. The Markov process considered 
12 health states (F0, F1, F2, F3, Compensated cirrhosis (F4), SVR, decompen-
sated cirrhosis, HCC, Transplantation (1 year), Transplantation (years later), 
HCV-related death and death from other causes) and 42 transition probabilities. 
The model was informed with available data published in national and interna-
tional literature. Effectiveness of new treatment strategies was estimated from 
literature review. Cumulative cases of HCV-related diseases, direct and indirect 
medical costs, avoided by the increased effectiveness of new treatments, were 
estimated. Results: The cohort of subjects with chronic HCV in 2013 amounts 
to 267.190 subjects, of these about 17,600 patients F3-F4 are treated with drug 
therapy. Cumulative cases of HCV-related diseases who succeed in preventing by 
the increased effectiveness of new treatments amounted to 47.433 after 7 years, 
156.507 after 17 years, 256.942 after 27 years. The direct net medical costs, after 
the cost of the drug, amounted to € 18,13, € 72,33 and € 143,24 millions after 7, 17 
and 27 years respectively, and € 166,51, € 950,3 and € 551,53 attributable to indirect 
costs avoided, for the same time horizons. Furthermore, it was estimated that each 
patient treated with new drugs achieves a reduction of expenditure of about € 12,000 
in terms of direct costs, and € 4,000 in terms of indirect costs. cOnclusiOns: In 
conclusion, an important share of the cost per treated patient can be compensated 
by the reduction of direct and indirect costs guaranteed by the effectiveness of new 
treatments.
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Objectives: While the practice of Health Technology Assessment (HTA) has been 
well established there is wide variation in the processes by which public reimburse-
ment decisions for vaccines are made in comparison to medicines and devices. 
The objective of this study was to compare the assessments of vaccines across 
Europe (UK, France, Germany, Italy, Spain), and to critically appraise the systems 
using the key principles for the conduct of HTA (Drummond et al, 2008). MethOds: 
A systematic review of economic modeling of vaccines, supplemented by a tar-
geted review of key stakeholder websites across Europe for previous assessments 
of vaccines was conducted. A search of Medline, Embase, Econlit and NHSEED was 
conducted and abstracts were reviewed by two independent reviewers against pre-
specified criteria for inclusion. Data from relevant articles was extracted and quality 
assessed. Country HTA websites were hand-searched. The evidence was synthesised 
to provide an overview of the strengths and weaknesses of the appraisal processes 
in each of the European countries. Results: The review highlighted the inher-
ent difficulties in health economic modeling using standard HTA processes as the 
long-term impact of vaccines is unknown, leading to wide variation in assumptions 
and methods of extrapolation. The literature identified highlighted the inherent 
uncertainty surrounding the long-term impact of vaccines, which directly impacts 
the cost-effectiveness. The review also highlighted the importance of budget 
impact of vaccines when making a decision. When compared to the key princi-
ples of HTA, all countries failed to meet all of the criteria. cOnclusiOns: The 
economic evaluations identified indicated that the cost-effectiveness of a vaccine 
was heavily dependent on the assumptions surrounding uptake and carriage. The 
review indicated that HTA decisions on vaccines are driven by cost-effectiveness 
and budget impact, which may lead to underestimating the potential clinical and 
public health benefits.
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Objectives: We performed national survey of behavior, attitudes and practice of 
general practitioners (GP) and specialists (pediatricians, ENT, pulmonologists) at 
the field of antimicrobial (ATB) use for respiratory tract infections. MethOds: A 
34-item iPad iOS survey was performed personally with each GP and specialist 
during 7 months period. Results: The survey was completed by 357 GPs and spe-
cialists (61,9% and 38,1%, respectively). GPs and specialists were situated mostly in 
areas with population higher than 5000 people (49,3% and 48,5%), but GPs served 
significantly more often in area with population less than 5000 people compared 
to specialists (P< 0,001, CI 0,13 – 0,60). There was significantly higher number of GPs 
with practice shorter than 5 years compared to specialists (P< 0,01, CI 0,02-0,64). 
GPs used their own clinical experience in prescribing ATB more often compare to 
specialists (61,1% vs 43,4%, P< 0,01, CI 0,31-0,77) and specialist used more often ATB 
susceptibility reports compared to GPs (18,4% vs 8,1%, P< 0,01, CI 1,27-5,10), which 
also corresponds with frequency of checking susceptibility reports on monthly basis 
Objectives: To document the proportion of national healthcare expenditures 
that is devoted to vaccines across Western Europe and its evolution over the past 
years. MethOds: Seven countries were selected: the 5 biggest countries in terms 
of population accounting for ≈317 million inhabitants in 2015 (Germany, England, 
France, Italy, and Spain) and 2 smaller countries from northern and southern 
Europe: Sweden and Portugal. This panel of countries constitutes a good mix of 
vaccine procurement modalities (centralized/decentralized, tender/reimburse-
ment) across Western Europe. Data search was performed on both OECD online 
databases and national official sources for healthcare and vaccine expendi-
tures from 2008 (2006 for England) until the most recent year available (usually 
2012/2013). Results: Healthcare expenditures have increased in all countries 
but Spain. Increases ranged from +3%/year in France to+6%/year in England. In 
the meantime, despite heterogeneous availability, vaccine spending diminished 
markedly in Germany (9%/year from 2008 to 2013), Spain (-7%/year from 2008 
to 2012) and France (-4%/year from 2008 to 2013). Only Sweden (SEK 1.72 Bn in 
2013, +6%/year from 2011 to 2013) and England (£0.40 Bn in 2010/11, +14%/year 
from 2006/07 to 2010/11) have increased their spending on vaccines. The pro-
portion of healthcare expenditures allocated to vaccines ranged from 0.45% in 
Germany (€ 0.82/182.7 Bn in 2013) down to 0.25% in Spain (€ 0.17/ 68.6 Bn in 2012) 
and France (€ 0.63/248 Bn in 2013). When available, OECD data showed similar 
proportions and evolution patterns in most cases. cOnclusiOns: Vaccination 
involves low levels of healthcare investments in Europe (< 0.5%) compared to 
the far-reaching public health benefits it procures. We evidenced a net trend 
towards a decrease over the past years, except for Sweden and England. In the 
ever-constraint budgetary context, vaccination budgets shall be preserved or even 
increased to sustain life-course approach of immunization at sufficient coverage 
rates.
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Objectives: To compare the total value of payer’s expenditures on Victrelis 
(boceprevir) and Incivo (telaprevir) in patients with chronic HCV GT1 estimated in 
the manufacturers’ Budget Impact Analyses (BIAs) submitted with the reimburse-
ment applications to AOTMiT and actual expenditures of the National Health Fund 
(NHF). MethOds: Annual public payer’s expenditures estimated in manufacturers’ 
BIAs for Victrelis and Incivo and actual expenditures reported by the NHF were com-
pared. RSSs were not taken into account. Analysed drugs were chosen on the basis 
of the same indication and financing through the same therapeutic programme 
in Poland. Actual expenditures and population size were taken from the finan-
cial reports of the NHF for the first and second year (actual data on 9 months for 
expenditures and 11 months for population size were extrapolated to one year) of 
reimbursement for each drug. Results: For drugs Victrelis and Incivo in patients 
with chronic HCV genotype 1 infections, the sum of total expenditures estimated 
in BIAs submitted with the reimbursement applications was 145,38 million PLN in 
the first year and 164,49 million PLN in the second year, and they were higher than 
the actual expenditures reported by the NHF: 77,48 million PLN and 120,72 million 
PLN, respectively. The expenditures estimated in BIAs were overestimated by 88% 
in the first year of reimbursement and 36% in the second year of reimbursement. 
Population size estimated in BIAs in comparison to its actual size from the NHF 
reports was overestimated by 53% in the first year and 38% in the second year 
of reimbursement. cOnclusiOns: In the case of drugs chosen for this analysis, 
total payer’s expenditures estimated in BIAs submitted with the reimbursement 
applications were overestimated in comparison to the real life expenditures of 
the NHF in Poland.
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Objectives: To assess the costs of vaccination throughout life for a fully immu-
nized Western European citizen. MethOds: Vaccines recommended in the most 
recent National Vaccination Calendar (NVC) for Germany, England, France, Italy, 
Spain, Sweden and Portugal were used differentiating men from women and healthy 
individuals from those suffering from underlying condition(s) who require specific 
additional vaccinations. Unit vaccine costs and administration fees were retrieved 
from national official sources. The number of visits was adjusted for possible co-
administrations to better reflect local vaccination practices. All costs were calculated 
from the national healthcare perspective. In sensitivity analyses, vaccine costs were 
varied within a +/-30% range to account for possible price variations due to competi-
tion, market type, size and vaccines lifecycle. Administration fees were increased 
by 30% hypothesizing that medical fees are unlikely to decline over time. Results: 
Vaccinating an individual against up to 19 diseases throughout his entire life and 
in full compliance with NVC would range from € 350 to € 2,400 (vaccines costs only) 
and from € 450 to € 3,400 when administration costs are considered. Lowest range 
corresponds to healthy man in Sweden and highest range to woman with underly-
ing conditions in England. Vaccination costs were variable among countries due 
to heterogeneous NVCs and vaccination organization. In all countries but France, 
adults (18-64y) and elderly (≥ 65) accounted for the lowest vaccines costs com-
pared to pediatric (0-24m) and children/adolescents (2-17y). In comparison, other 
mass secondary prevention may be at least 3 times more costly. cOnclusiOns: 
Vaccination requires a relatively low amount of money per individual knowing that 
some missed opportunities remain in senior vaccinations. A life-course approach 
of vaccination should be considered as a smart investment providing substantial 
benefit falling actually well beyond individual health and protecting the whole 
